Copy Link Print Information

Upadacitinib

(Synonyms: ABT-494)
27 Cited Publications
Kundenbewertung

Based on 27 publication(s) in Google Scholar

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.98%
  • CAS. Nr.: 1310726-60-3
  • Formel: C17H19F3N6O
  • Molecular Weight:380.37
  • Speicherung:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Upadacitinib Chemical Structure
    Upadacitinib Chemical Structure
  • Experimental Validation Results for Upadacitinib
  • Experimental Validation Results for Upadacitinib
  • Experimental Validation Results for Upadacitinib
  • Experimental Validation Results for Upadacitinib
  • Experimental Validation Results for Upadacitinib
CAS. Nr.: 1310726-60-3
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Upadacitinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Upadacitinib

More
Customer Validation & Images
Flow CytometryELISACell Proliferation/Viability AssayRT-PCR
  • ELISA
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • Flow Cytometry
  • Flow Cytometry

Alle JAK Isoform-spezifische Produkte anzeigen

More
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Upadacitinib Chemical Structure
    Upadacitinib Chemical Structure
    1/16
  • 1/16

    Upadacitinib purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. [Abstract]

    Customer Validation
     PBLs isolated from healthy participants (n = 6) were pretreated with either vehicle control (0.01% DMSO) or JAK inhibitor Upadacitinib (1 µM, 100 nM, 10 nM) before LPS stimulation. Secreted IL-6 and IL-1β were measured by ELISA 48 hours post-stimulation.

  • 1/16

    Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 29;16(1):6972. [Abstract]

    Customer Validation
     Cell survival of SUM149 BRCA1-Mut and BRCA1-Rev cells transfected with a concentration range (nM) of ADAR1 siRNA in the context of exposure to the JAK/STAT pathway inhibitor Upadacitinib ( 32 µM).

  • 1/16

    Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]

    Customer Validation
     Human melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.

  • 1/16

    Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]

    Customer Validation
     Mouse melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.

  • 1/16

    Upadacitinib purchased from MedChemExpress. Usage Cited in: Cell. 2024 Jan 4;187(1):44-61.e17. [Abstract]

    Customer Validation
     Schematic of vehicle (Veh) or Upadacitinib (Upa) (2.5 mg/kg; administered intranasally; twice daily for four consecutive days) treatment of ALT-induced allergic lung inflammation in WT mice. Flow cytometry of lung tissue from vehicle- or upadacitinib-treated mice challenged with intranasal ALT. Shown are the frequencies of ILC2s and eosinophils.

  • Upadacitinib